Published in BMC Cancer on January 22, 2013
Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol (2013) 1.09
Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel. Radiat Oncol (2015) 0.79
Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer. Prostate Cancer (2015) 0.78
Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients. Radiol Oncol (2016) 0.75
Long-term intra-fractional motion of the prostate using hydrogel spacer during Cyberknife® treatment for prostate cancer--a case report. Radiat Oncol (2014) 0.75
Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives. Cancer Manag Res (2017) 0.75
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys (1995) 15.12
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol (2007) 5.00
Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys (2010) 3.83
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 3.61
Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol (2006) 3.12
Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys (2011) 2.96
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys (2007) 2.41
Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 2.33
Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys (2009) 2.26
Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.80
A novel device for protecting rectum during prostate cancer irradiation: in vivo data on a large mammal model. J Urol (2009) 1.50
Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.45
Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.43
Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.37
Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys (2009) 1.19
Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.13
Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol (2011) 1.12
Application technique: placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int (2012) 1.08
Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.08
Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy (2009) 1.04
Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities. Radiother Oncol (2005) 0.98
Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.97
Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol (2011) 0.96
Normal tissue dose-effect models in biological dose optimisation. Z Med Phys (2008) 0.87
Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy. Brachytherapy (2010) 0.83
Late fecal incontinence after high-dose radiotherapy for prostate cancer: better prediction using longitudinal definitions. Int J Radiat Oncol Biol Phys (2011) 0.82
Patients' perspectives on fecal incontinence after brachytherapy for localized prostate cancer. Dis Colon Rectum (2011) 0.79
Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity-modulated brachytherapy or EBRT for prostate cancer patients: in regard to Prada et al. (Int J Radiat Oncol Biol Phys 2007;69:95-102.). Int J Radiat Oncol Biol Phys (2008) 0.77
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol (2010) 3.88
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
The periprostatic autonomic nerves--bundle or layer? Eur Urol (2008) 2.38
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol (2005) 2.00
Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy. BJU Int (2012) 1.99
Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection. JAMA Ophthalmol (2013) 1.99
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med (2005) 1.81
Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. J Clin Oncol (2006) 1.73
Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol (2012) 1.72
ERG rearrangement in small cell prostatic and lung cancer. Histopathology (2010) 1.64
Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience. Oncologist (2007) 1.63
Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci (2004) 1.62
Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol (2006) 1.61
Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer (2005) 1.57
Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys (2007) 1.51
Urethral ultrasound as a screening tool for stricture recurrence after oral mucosa graft urethroplasty. Urology (2011) 1.50
Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria. Adv Urol (2011) 1.49
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol (2006) 1.43
Dorsal onlay skin graft urethroplasty in patients older than 65 years. Urology (2010) 1.41
CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging (2013) 1.39
Steerable antegrade stenting: a new trick of the trade. Int Braz J Urol (2007) 1.39
Urinary calculi composed of uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a radiation dose comparable to that of intravenous pyelography. Radiology (2010) 1.39
A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol (2005) 1.38
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol (2010) 1.33
Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol (2006) 1.32
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol (2002) 1.32
Catheter ablation of atrial fibrillation using the Navx-/Ensite-system and a CT-/MRI-guided approach. Clin Res Cardiol (2009) 1.31
Current concepts in the classification, diagnosis and treatment of vascular anomalies. Eur J Radiol (2010) 1.30
Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol (2006) 1.30
Benchmarking the quality of breast cancer care in a nationwide voluntary system: the first five-year results (2003-2007) from Germany as a proof of concept. BMC Cancer (2008) 1.27
Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol (2009) 1.23
MR Imaging of the heart with cine true fast imaging with steady-state precession: influence of spatial and temporal resolutions on left ventricular functional parameters. Radiology (2002) 1.18
[18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging (2003) 1.18
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol (2009) 1.16
NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol (2005) 1.16
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys (2009) 1.16
Multislice first-pass myocardial perfusion imaging: Comparison of saturation recovery (SR)-TrueFISP-two-dimensional (2D) and SR-TurboFLASH-2D pulse sequences. J Magn Reson Imaging (2004) 1.14
Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol (2009) 1.13
Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol (2007) 1.13
Perfusion MR imaging with FAIR true FISP spin labeling in patients with and without renal artery stenosis: initial experience. Radiology (2006) 1.11
18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2006) 1.11
Closing the tract of mini-percutaneous nephrolithotomy with gelatine matrix hemostatic sealant can replace nephrostomy tube placement. Urology (2006) 1.10
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest (2010) 1.09
Fibrotic changes after postmastectomy radiotherapy and reconstructive surgery in breast cancer. A retrospective analysis in 109 patients. Strahlenther Onkol (2010) 1.09
Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol (2003) 1.08
Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer. Lung Cancer (2003) 1.08
Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys (2010) 1.07
Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2002) 1.06
Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol (2002) 1.06
Cancer stem cells and radiotherapy. Int J Radiat Biol (2009) 1.06
Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol (2012) 1.04
Differentiation of urinary calculi with dual energy CT: effect of spectral shaping by high energy tin filtration. Invest Radiol (2010) 1.04
Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol (2007) 1.02
Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol (2008) 1.01
Can we still afford bladder cancer? Curr Opin Urol (2008) 1.01
Minimally invasive percutaneous nephrolitholapaxy (PCNL) as an effective and safe procedure for large renal stones. BJU Int (2012) 1.01
Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity. Strahlenther Onkol (2003) 1.01
Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol (2003) 1.00
Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol (2007) 1.00
Atherosclerotic disease: whole-body cardiovascular imaging with MR system with 32 receiver channels and total-body surface coil technology--initial clinical results. Radiology (2005) 0.99
Advances in the treatment of testicular cancer. Drugs (2006) 0.99
Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol (2003) 0.99
A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys (2007) 0.99
Decreased 3D observer variation with matched CT-MRI, for target delineation in Nasopharynx cancer. Radiat Oncol (2010) 0.99
Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2006) 0.98
Small renal oncocytomas: differentiation with multiphase CT. Eur J Radiol (2010) 0.97
Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol (2002) 0.97
The HOPE fixation technique--a promising alternative to common prostate cancer biobanking approaches. BMC Cancer (2011) 0.97
Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU Int (2009) 0.96
EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells. Cancer Res (2012) 0.96
Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer (2005) 0.96
Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol (2002) 0.96
Dual-source CT with improved temporal resolution in assessment of left ventricular function: a pilot study. AJR Am J Roentgenol (2007) 0.96
Tumorsize dependent detection rate of endorectal MRI of prostate cancer--a histopathologic correlation with whole-mount sections in 70 patients with prostate cancer. Eur J Radiol (2010) 0.95
Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem (2002) 0.95
Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys (2002) 0.95
Risk of second malignancies after prostate irradiation? Strahlenther Onkol (2007) 0.94
External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys (2006) 0.94
Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys (2007) 0.94
Radiation therapy alone in early stage non-small cell lung cancer. Semin Surg Oncol (2003) 0.94
Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys (2011) 0.94
Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. Int J Radiat Oncol Biol Phys (2011) 0.93
Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care. BMC Cancer (2009) 0.93
A strategy for multimodal deformable image registration to integrate PET/MR into radiotherapy treatment planning. Acta Oncol (2013) 0.93